Drugmaker Merck said on Tuesday it expects its top selling cancer therapy Keytruda to be selected in 2026 for government ...

We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors should consider selling the same.

Merck is bracing for the years of sales growth from oncology superstar Keytruda to take a sharp turn in 2028—and for more ...

Merck (MRK) said it expects its top-selling drug, Keytruda, to be selected by the U.S. government for price setting ...

Keytruda has been approved since 2016 as a second-line option after chemotherapy for patients with more advanced HNSCC that ...

Keytruda demonstrated a statistically significant and clinically meaningful improvement in event-free survival and major ...

Eli Lilly LLY announced that it is increasing its manufacturing capacity in the United States by building four new plants.

Merck's Q4 2024 results surpassed expectations, driven by strong oncology sales and growth in Keytruda. See why I think MRK ...

An expert shares information on a pair of noteworthy active trials in breast cancer that patients should be aware of.

The US Food and Drug Administration (FDA) has accepted for priority review a new supplemental Biologics License Application ...

The FDA accepted for priority review a supplemental Biologics License Application for Keytruda for resectable locally ...